natgillin/translations-raw huggingface dataset:
There have been reports of hypogammaglobulinaemia in association with recurrent infections in patients receiving mycophenolate mofetil in combination with other immunosuppressants. 
Prijavljeni su slučajevi hipogamaglobulinemije povezani s rekurentnim infekcijama kod bolesnika koji su primali mofetilmikofenolat u kombinaciji s drugim imunosupresivima.
The most common opportunistic infections in patients receiving mycophenolate mofetil (2°g or 3°g daily) with other immunosuppressants in controlled clinical trials in renal (2°g data), cardiac and hepatic transplant patients followed for at least 1°year were candida mucocutaneous, cytomegalovirus (CMV) viraemia/syndrome and Herpes simplex. 
Najčešće oportunističke infekcije koje se pojavljuju kod bolesnika koji primaju mofetilmikofenolat (2 g ili 3 g dnevno) uz druge imunosupresive u kontroliranim kliničkim ispitivanjima u bolesnika s presađenim bubregom (podaci o dozi od 2 g), srcem i jetrom, tijekom praćenja od barem godinu dana, bile su mukokutana kandidijaza,
Convulsion, hypertonia, tremor, somnolence, myasthenic syndrome, dizziness, headache, paraesthesia, dysgeusia 
Poremećaji živčanog sustava vrlo često često konvulzije, hipertonija, tremor, somnolencija, mijastenični sindrom, omaglica, glavobolja, parestezija, disgeuzija
• The active substance is mycophenolate mofetil. 
• Djelatna tvar je mofetilmikofenolat.
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by coadministration with tacrolimus. 
Kod primatelja s presađenom jetrom kod kojih je započeto liječenje mofetilmikofenolatom i takrolimusom, razine takrolimusa nisu značajnije utjecale na AUC i Cmax MPA, aktivnog metabolita mofetilmikofenolata.
Myfenax 500 mg film-coated tablets 
Myfenax 500 mg filmom obložene tablete
This means taking 2°tablets in the morning then 2°tablets in the evening. 
To znači da se 2 tablete uzimaju ujutro, a
Hypersensitivity reactions to Myfenax have been observed (see section 4.8). 
Myfenax (vidjeti dio 4.8).
Adverse reactions, probably or possibly related to mycophenolate mofetil, reported in ≥1/10 and in ≥1/100 to <1/10 of patients treated with mycophenolate mofetil in the controlled clinical trials of renal (2°g data), cardiac and hepatic transplant patients are listed in the following table. 
Nuspojave, vjerojatno ili moguće povezane sa mofetilmikofenolatom, prijavljene u kontroliranim kliničkim ispitivanjima bolesnika s presađenim bubregom (podaci za dozu od 2 g), srcem ili jetrom kod ≥1/10 i ≥1/100 do <1/10 bolesnika liječenih mofetilmikofenolatom, navedene su u sljedećoj tablici.
The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18°years who were given 600°mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1°g mycophenolate mofetil twice daily. 
do 18 godina, koji su peroralno primali 600 mg/m2 mofetilmikofenolata dvaput dnevno, bila je uglavnom slična onima uočenima kod odraslih bolesnika koji su uzimali 1 g mofetilmikofenolata dvaput dnevno.
Isavuconazole An increase of MPA AUC0-∞ by 35% was observed with concomitant administration of isavuconazole. 
Kod istodobne primjene izavukonazola primijećen je porast AUC0-∞ MPA-a za 35%.
Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil (see section 4.4). 
Poremećaji krvi i limfnog sustava Prijavljeni su slučajevi izolirane aplazije eritrocita (PRCA) kod bolesnika liječenih mofetilmikofenolatom (vidjeti dio 4.4).
The systemic exposure at this dose was approximately 0.5°times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3°times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients. 
Sistemska izloženost pri ovoj dozi iznosila je otprilike 0,5 puta od kliničke izloženosti pri preporučenoj kliničkoj dozi od 2 g/dan za bolesnike s presađenim bubregom i otprilike 0,3 puta od kliničke izloženosti pri preporučenoj kliničkoj dozi od 3 g/dan kod bolesnika s presađenim srcem.
The pharmacokinetics of oral contraceptives were unaffected by co-administration of mycophenolate mofetil (see also section 4.5). 
Istodobna primjena mofetilmikofenolata nije utjecala na farmakokinetiku oralnih kontraceptiva (vidjeti i dio 4.5).
Myfenax should not be given to women who are breastfeeding (see section 4.6). 
Myfenax ne smije se davati dojiljama (vidjeti dio 4.6).
Precautions to be taken before handling or administering the medicinal product Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Myfenax tablets should not be crushed. 
Budući da je mofetilmikofenolat pokazao teratogene učinke kod štakora i kunića, Myfenax tablete ne smiju se drobiti.
Keep this medicine out of the sight and reach of children. 
Kako čuvati Myfenax Lijek čuvajte izvan pogleda i dohvata djece.
Sími: +354 5222900 
Alvogen ehf. Sími: +358 5222900
Contact your nearest hospital Accident and Emergency department or a doctor for advice if you have swallowed more capsules than you have been told to take or if you think a child has swallowed any. 
Ako popijete više kapsula nego što Vam je propisano ili ako mislite da je Vaše dijete progutalo kapsulu, za savjet se obratite na odjel hitne službe u najbližoj bolnici ili svom liječniku.
• infection of the digestive tract 
• infekcija probavnog sustava
Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil in combination with other immunosuppressants. 
Pure Red Cell Aplasia, PRCA) kod bolesnika liječenih mofetilmikofenolatom u kombinaciji s drugim imunosupresivima.
Spontaneous abortion (rate of 45% to 49%) and congenital malformations (estimated rate of 23% to 27%) have been reported following MMF exposure during pregnancy. 
Nakon izlaganja mofetilmikofenolatu tijekom trudnoće prijavljeni su spontani pobačaj (stopa od 45% do 49%) i kongenitalne malformacije
Medicinal products that interfere with enterohepatic circulation (e.g. cholestyramine, ciclosporin A, antibiotics) 
Lijekovi koji utječu na glukuronidaciju (npr. izavukonazol, telmisartan)
Indigo carmine (E132) 
Kapica indigo karmin (E132) titanijev dioksid (E171) želatina
Patients receiving Myfenax should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression. 
Bolesnike koji primaju Myfenax potrebno je uputiti da odmah prijave bilo koji znak infekcije,
Povidone K-30 
IgG-a na normalu.
The systemic exposure at this dose represents 2-3°times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3-2°times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients. 
Sistemska izloženost pri tim dozama je 2 - 3 puta veća od kliničke izloženosti pri preporučenoj kliničkoj dozi od 2 g/dan kod bolesnika s presađenim bubregom i 1,3 - 2 puta veće od kliničke izloženosti pri preporučenoj kliničkoj dozi od 3 g/dan kod bolesnika s presađenim srcem.
Body: caramel opaque, printed ‘250' axially in black ink. 
Tijelo: neprozirno, boje karamela s oznakom ‘250' uzdužno utisnutom crnom tintom Kapica: neprozirna, svijetlo plava s oznakom ‘M' uzdužno utisnutom crnom tintom.
Mycophenolate mofetil had no effect on fertility of male rats at oral doses up to 20 mg/kg/day. 
Pri oralnim dozama do 20 mg/kg/dan, mofetilmikofenolat nije utjecao na plodnost muških štakora.
Myfenax 250mg hard capsules Mycophenolate mofetil 
Myfenax 250 mg tvrde kapsule mofetilmikofenolat
• serious diseases of the bone marrow 
• problemi s bubrezima
Pleural effusion, dyspnoea, cough 
stomatitis, konstipacija, dispepsija, flatulencija, eruktacija
• The Package Leaflet 
• začepljena crijeva
In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g taken twice a day [BID], morning and evening) were administered to hepatic transplant patients taking tacrolimus. 
Međutim, u bolesnika s presađenom jetrom koji su uzimali takrolimus, došlo je do povećanja AUC-a takrolimusa za otprilike 20 % pri uzimanju višestrukih doza mofetilmikofenolata (1,5 g dvaput dnevno, ujutro i uvečer) (vidjeti i dio 4.4).
Hepatitis, jaundice, hyperbilirubinaemia 
Poremećaji jetre i žuči vrlo često često hepatitis, žutica, hiperbilirubinemija
Yellow iron oxide (E172) 
Tijelo crveni željezov oksid (E172) žuti željezov oksid (E172) titanijev dioksid (E171) želatina
No data are available for cardiac transplant patients with severe hepatic parenchymal disease. 
Nema podataka o primjeni u bolesnika s presađenim srcem i teškim oštećenjem jetrenog parenhima.
Trimethoprim/sulfamethoxazole No effect on the bioavailability of MPA was observed. 
Nije opažen učinak na bioraspoloživost MPA-a.
The recommended dose in cardiac transplant patients is 1.5°g administered twice daily (3°g daily dose). 
Preporučena doza za bolesnike s presađenim srcem iznosi 1,5 g dvaput dnevno (dnevna doza od 3 g).
Contact your nearest hospital Accident and Emergency department or a doctor for advice if you have swallowed more tablets than you have been told to take or if you think a child has swallowed any. 
Ako popijete više tableta nego što Vam je propisano ili ako mislite da je Vaše dijete progutalo tabletu, za savjet se obratite na odjel hitne službe u najbližoj bolnici ili svom liječniku.
The recommended oral dose in hepatic transplant patients is 1.5°g administered twice daily (3°g daily dose). 
Preporučena oralna doza za bolesnike s presađenom jetrom iznosi 1,5 g dvaput dnevno (dnevna doza od 3 g).
• Are you taking any medicines containing: o azathioprine or other immunosuppressive agents (which are sometimes given to patients after a transplant operation), o cholestyramine (used to treat patients with high blood cholesterol), o rifampicin (antibiotic), o antacids or proton pump inhibitors (used for acid problem in your stomach such as indigestion), o phosphate binders (used in patients with chronic kidney failure to reduce the absorption of phosphate), o antibiotics (used to treat bacterial infections), o isavuconazole (used to treat fungal infections), o telmisartan (used to treat high blood pressure) o or any other medicines (including those you can buy without a prescription) that your doctor does not know about? 
• Uzimate li bilo koji lijek koji sadrži o azatioprin ili druge imunosupresivne lijekove (koji se ponekad daju bolesnicima nakon presađivanja), o kolestiramin (koristi se za liječenje bolesnika s visokim kolesterolom u krvi),
The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose). 
Preporučena doza za bolesnike s presađenim bubregom iznosi 1 g dvaput dnevno (dnevna doza od 2 g).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 
Dobroćudne, zloćudne i nespecificirane novotvorine
Alvogen ehf. 
PRILOG III.
Gastrointestinal haemorrhage, peritonitis, ileus, colitis, gastric ulcer, duodenal ulcer, gastritis, oesophagitis, stomatitis, constipation, dyspepsia, flatulence, eructation 
želučani ulkus, ulkus dvanaesnika, gastritis, ezofagitis,
Conversely, changes of MPA exposure should be expected when switching patients from CsA to one of the immunosuppressants which does not interfere with MPA´s enterohepatic cycle. 
na neki od imunosupresiva koji ne interferiraju s enterohepatičnom cirkulacijom MPA, treba očekivati promjene u izloženosti MPA-u.
Capsule shell 
Ovojnica kapsula
By interfering with enterohepatic circulation of the drug, bile acid sequestrants such as cholestyramine, reduce MPA AUC (see section 4.9). 
poput kolestiramina, snizuju AUC MPA (vidjeti dio 4.9).
Croscarmellose sodium 
Trimetoprim/sulfametoksazol
Hypromellose (HPMC 2910) Titanium dioxide (E171) Macrogol (PEG 400) Talc 
Ovojnica tablete hipromeloza (HPMC 2910) titanijev dioksid (E171) makrogol (PEG 400) talk indigo carmine aluminium lake (E132) željezov oksid, crni (E172) željezov oksid, crveni (E172)
Paediatric population aged 2 to 18 years The recommended dose of mycophenolate mofetil is 600 mg/m2 administered orally twice daily (up to a maximum of 2 g daily). 
Preporučena doza mofetilmikofenolata iznosi 600 mg/m2, primjenjena oralno dvaput dnevno (najviše
Agitation, confusional state, depression, anxiety, thinking abnormal, insomnia 
Psihijatrijski poremećaji vrlo često često agitacija, konfuzno stanje, depresija, anksioznost,
The recommended dose of 1°g administered twice a day for renal transplant patients and 1.5°g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly. 
Za starije se osobe preporučuje doza od 1 g dvaput dnevno ako im je presađen bubreg te 1,5 g dvaput dnevno ako im je presađeno srce ili jetra.
System organ class Frequency Adverse drug reactions 
Klasifikacija organskih sustava
Capsule content 
Ovojnica kapsule
PRCA may resolve with dose reduction or cessation of Myfenax therapy. 
MPA pa nije potrebno smanjiti dozu ni prekinuti primjenu Myfenaxa.
Myfenax should be administered with caution in patients with active serious digestive system disease. 
Kod bolesnika s aktivnom ozbiljnom bolešću probavnog sustava Myfenax se mora primjenjivati s oprezom.
Arthralgia 
Takrolimus
• fungal infection of the digestive tract 
• gljivična infekcija probavnog sustava • infekcija mokraćnog sustava
Therefore, a change in the dose of Myfenax should not normally be necessary in the absence of clinical evidence of graft dysfunction. 
Stoga, ako nema kliničkih dokaza disfunkcije presatka, promjena doze mofetilmikofenolata obično nije potrebna.
• The active substance is mycophenolate mofetil. Each tablet contains 500mg of mycophenolate mofetil. 
• Djelatna tvar je 500 mg mofetilmikofenolata.
Myfenax 500mg film-coated tablets Mycophenolate mofetil 
Myfenax 500mg filmom obložene tablete mofetilmikofenolat
How to store Myfenax 
Moguće nuspojave Kako čuvati Myfenax
The highest dose tested in the animal carcinogenicity studies resulted in approximately 2-3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/day and 1.3-2°times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3 g/day. 
(AUC ili Cmax) od primijećene kod bolesnika s presađenim bubregom pri preporučenoj kliničkoj dozi od 2 g/dan te 1,3 - 2 puta većom sistemskom izloženošću(AUC ili Cmax) od primijećene kod bolesnika s presađenim srcem pri preporučenoj kliničkoj dozi od 3 g/dan.
• chest cold, sore throat, inflammation of the sinuses, stuffy and runny nose, sneezing 
• upala bronha, upala grla, upala sinusa, začepljen nos i curenje iz nosa, kihanje • rak kože izrasline na koži koje nisu povezane sa rakom
The highest dose tested in the animal carcinogenicity studies resulted in approximately 2-3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/day and 1.3-2 times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3 g/day. 
(AUC ili Cmax) od primijećene kod bolesnika s presađenim bubregom pri preporučenoj kliničkoj dozi od 2 g/dan te 1,3 - 2 puta većom sistemskom izloženošću (AUC ili Cmax) od primijećene kod bolesnika s presađenim srcem pri preporučenoj kliničkoj dozi od 3 g/dan.
Medicinal products that affect glucuronidation (e.g. isavuconazole, telmisartan) Concomitant administration of drugs inhibiting glucuronidation of MPA may increase MPA exposure. 
Istodobna primjena lijekova koji inhibiraju glukuronidaciju MPA-a može povećati izloženost MPA-u.
• Congenital choroid plexus cyst; 
• prirođene ciste na koroidnom pleksusu
Very common Sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster 
citomegalovirusna (CMV) viremija/sindrom i herpes simpleks.
• Tracheo-Oesophageal malformations (e.g. oesophageal atresia); 
česte infekcije) (agranulocitoza)
System organ class Frequency Adverse drug reactions hypercholesterolaemia, hyperlipidaemia, hypophosphataemia, hyperuricaemia, gout, anorexia Psychiatric disorders Very commonCommon 
Poremećaji krvi i limfnog sustava vrlo često leukopenija, trombocitopenija, anemija često pancitopenija, leukocitoza
Lymphoproliferative disease or lymphoma developed in 0.6% of patients receiving mycophenolate mofetil (2°g or 3°g daily) in combination with other immunosuppressants in controlled clinical trials of renal (2°g data), cardiac and hepatic transplant patients followed for at least 1°year. 
bolesnika koji su primali mofetilmikofenolat (2 g ili 3 g dnevno) u kombinaciji s drugim imunosupresivima, došlo je do razvoja limfoproliferativne bolesti ili limfoma.
Skin hypertrophy, rash, acne, alopecia 
Poremećaji kože i potkožnog tkiva vrlo često često hipertrofija kože, osip, akne, alopecija
Excipient 
OBLIK
The mean bioavailability of oral mycophenolate mofetil, based on MPA AUC, is 94% relative to intravenous mycophenolate mofetil. Food had no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil when administered at doses of 1.5°g BID to renal transplant patients. 
Hrana nema utjecaj na veličinu apsorpcije (AUC-a MPA) mofetilmikofenolata kad se kod bolesnika s presađenim bubregom primjenjuje u dozama od 1,5 g dvaput dnevno.
Name and address of the manufacturers responsible for batch release 
Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet Teva Pharmaceutical Works Private Limited Company Pallagi út 13.
Skin and subcutaneous tissue disorders 
• herpes i herpes zoster
Kidney Transplant 
Presađivanje bubrega
• Before you start taking Myfenax 
To uključuje: • razdoblje prije početka uzimanja lijeka Myfenax
Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Myfenax is not required. 
Myfenax je lijek za suprimiranje imunološke aktivnosti Djelatna tvar u ovom lijeku zove se mofetilmikofenolat.
You must not donate blood during treatment with Myfenax and for at least 6 weeks after stopping treatment. 
Tijekom liječenja lijekom Myfenax i najmanje 6 tjedana nakon prestanka liječenja ne smijete darivati krv.
• inflammation of the digestive tract 
• upala probavnog sustava
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). 
Bolesnici koji primaju imunosupresivnu terapiju koja obuhvaća kombinaciju lijekova, uz ostalo i mofetilmikofenolat, izloženi su povećanom riziku od nastajanja limfoma i drugih zloćudnih bolesti,
Cyprus domperidone Costi 
Cyprus domperidon Costi
Diagonal, 67-69 Barcelona 
Diagonal, 67-69
Str. Fabricii nr. 124, Cluj Napoca, Romania 
Fabricii nr. 124, Cluj Napoca, Romania
Domperidone COSTI 
Domperidon COSTI
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the Member States 
Popis naziva, farmaceutskih oblika, jačina lijekova, puteva primjene, nositelja odobrenja u državama članicama
Via Nocera Umbra 75, 00181 Roma 
Via Nocera Umbra 75, 00181 Roma Italy
Domperidone NEOPERIDYS 
Domperidon NEOPERIDYS
10 mg capsule, hard 
10 mg kapsula, tvrda
United Kingdom Athlone Pharmaceuticals Limited, Ballymurray, Roscommon, Co. 
Athlone Pharmaceuticals Limited, Ballymurray, Roscommon, Co.
Johnson & Johnson D.O.O Smartinska cesta 53 1000 Ljubljana Slovenia domperidone Motilium 
Johnson & Johnson D.O.O Smartinska cesta 53 1000 Ljubljana Slovenia domperidon Motilium
LABORATORIOS DR. ESTEVE, S.A. Avda. 
Španjolska LABORATORIOS DR. ESTEVE, S.A. Avda.
4230 Skaelskoer Denmark domperidone Domperidon "Alternova" 
4230 Skaelskoer Denmark domperidon Domperidon "Alternova"
150 00 Praha 5 - Smíchov Czech Republic domperidone Motilium 
150 00 Praha 5 - Smíchov Czech Republic domperidon Motilium
Belgium domperidone Motilium Domperidone Base 
Belgium domperidon Motilium Domperidone Base
Šmarješka cesta 6 8501 Novo mesto Slovenia domperidone Tametil 10 mg filmsko obložene tablete 
Šmarješka cesta 6 8501 Novo mesto Slovenia domperidon Tametil 10 mg filmsko obložene tablete
Belgium domperidone Motilium-10 supp. 
Belgium domperidon Motilium-10 supp.
mg/100 ml syrup 
mg/100 ml sirup
Wise Pharmaceuticals Ltd. 
Nizozemska Wise Pharmaceuticals Ltd.
Lagoas Park, Edifício 5 A, Piso 2 2740-245 Porto Salvo Portugal domperidone Domperidona Ratiopharm 
Lagoas Park, Edifício 5 A, Piso 2 2740-245 Porto Salvo Portugal domperidon Domperidona Ratiopharm
Athens, Greece domperidone OROPERIDYS 
Athens, Greece domperidon OROPERIDYS
Samenwerkende Apothekers Nederland B.V. 
Nizozemska Samenwerkende Apothekers Nederland B.V.
10 mg/10 ml suspension 
10 mg/10 ml suspenzija
Limassol CY-3505 Cyprus domperidone Costi 10mg Film coated tablets 
Limassol CY-3505 Cyprus domperidon Costi 10mg Film coated tablets
Greece domperidone CILROTON 
Greece domperidon CILROTON
3460 Birkeroed Denmark domperidone Motilium 
3460 Birkeroed Denmark domperidon Motilium
H-2045 Törökbálint Hungary domperidone Motilium 10 mg filmtabletta 
H-2045 Törökbálint Hungary domperidon Motilium 10 mg filmtabletta
Avenida do Forte, 3 - Edificio Suécia III, Piso 1 
ToLife - Produtos Farmacêuticos, S.A. Avenida do Forte, 3 - Edificio Suécia III, Piso 1
MEDOCHEMIE LTD 1-10 Constantinoupoleos Str, P.O.Box 51409, Lemesos Cyprus domperidone COSTI TABLETS 10MG 
MEDOCHEMIE LTD 1-10 Constantinoupoleos Str, P.O.Box 51409, Lemesos Cyprus domperidon COSTI TABLETS 10MG 10 mg tableta
UAB „Johnson & Johnson“ Geležinio Vilko g. 18A LT-08104 Vilnius Lithuania domperidone Motilium 10 mg filmcoated tablets 
UAB „Johnson & Johnson“ Geležinio Vilko g. 18A LT-08104 Vilnius Lithuania domperidon Motilium 10 mg filmcoated tablets
Luxembourg Johnson & Johnson Consumer N.V. Antwerpseweg 15-17 
Luksemburg Johnson & Johnson Consumer N.V. Antwerpseweg 15-17
United Kingdom Co-operative Pharmacy National Distribution Centre Limited, Enterprose Way, Meir Park, Stokeon-Trent, Staffordshire ST3 7UN United Kingdom domperidone maleate 
Co-operative Pharmacy National Distribution Centre Limited, Enterprose Way, Meir Park, Stokeon-Trent, Staffordshire ST3 7UN United Kingdom domperidon maleat
Domperidone Domperidone instant EG 
Domperidon Domperidone instant EG
Domperidone PYNINAT 
Domperidon PYNINAT
Labesfal Genéricos, S.A Avenida Dr. Afonso Costa, 1370 3465-051 Campo de Besteiros Portugal domperidone Domperidona Labesfal 
Labesfal Genéricos, S.A Avenida Dr. Afonso Costa, 1370 3465-051 Campo de Besteiros Portugal domperidon Domperidona Labesfal 10 mg tableta
Domperidone DALIA 
Domperidon DALIA
United Kingdom Milpharm Limited, Ares Block, Odyssey Business Park, West End Road, Ruislip, HA4 6QD, United Kingdom domperidone maleate 
Milpharm Limited, Ares Block, Odyssey Business Park, West End Road, Ruislip, HA4 6QD, United Kingdom domperidon maleat
PENSA PHARMA, S.A.U. 
Španjolska PENSA PHARMA, S.A.U.
Domperidone DOMPERIDONE GERMED 
Domperidon DOMPERIDONE GERMED
Domperidone DOMPERIDONE TEVA 
Domperidon teva
Belgium Kela Pharma nv Industriepark 68 
Nizozemska KELA Pharma nv Industriepark West 68
Actavis A/S Sucursal Rua Virgílio Correia, 11 - A 1600-219 Lisboa Portugal domperidone Domperidona Actavis 
Actavis A/S Sucursal Rua Virgílio Correia, 11 - A 1600-219 Lisboa Portugal domperidon Domperidona Actavis 10 mg tableta
1 mg/ml suspension 
1 mg/ml suspenzija
Domperidone Domperidona Gamir 10 mg cápsulas duras 
Domperidon Domperidona Gamir 10 mg cápsulas duras
Domperidone RAXAR 
Domperidon RAXAR
United Kingdom McNeil Products Limited, Johnson & Johnson Ltd, Foundation Park, Roxborough Way, Maidenhead, Berkshire SL6 3UG, 
McNeil Products Limited, Johnson & Johnson Ltd, Foundation Park, Roxborough Way, Maidenhead, Berkshire SL6 3UG, United Kingdom
Parque Expo, Edifício Atlantis, Avenida D. João II, Lote 1.06.2.2 C - 7.3 e 7.4 
João II, Lote 1.06.2.2 C7.3 e 7.4